All In Biotech

Drug Trial Radar · NCT06793826

Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

Post-marketing Surveillance Study for the Safety of Hexaxim®, a DTaP-IPV- HB-PRP~T Vaccine Administered to Infants From 2 Months of Age in Republic of Korea

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

713

Actual

Start

Jan 17, 2025

Primary completion

Jan 15, 2026

Study completion Jan 15, 2026

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 2 months, up to 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary objectives: To investigate the incidence of adverse events occurred following administration of Hexaxim in infants from 2 months of age under routine clinical practice, as per approved indications

Conditions

  • Hepatitis B
  • Haemophilus Influenzae Type b Immunisation

Interventions

  • DTaP-IPV-Hep B-PRP-T combined vaccineBiological

    prefilled syringe injection intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting immediate adverse events/adverse drug reactions (AEs/ADRs)Time frame: Within 30 minutes post-vaccination
  2. Number of participants reporting serious adverse events / adverse drug reactions (SAEs / SADRs)Time frame: Up to 43 days post-vaccination
  3. Number of participants reporting solicited injection site and systemic reactionsTime frame: Up to 7 days post-vaccination
  4. Number of participants reporting unsolicited non-serious AEs/ADRsTime frame: Up to 28 days post-vaccination

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 002

    Cheonan, South Korea

  • Investigational Site Number : 001

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.